Galicaftor

Small moleculeexperimental

Clinical trial activity

12 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jan 1, 2016 (NCT02662452)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(O)c1ccc([C@H]2C[C@@H](NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c3ccc(OC(F)F)cc3O2)cc1
Mol. weight
559.47 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • glpg2222

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07035990Phase 1Jul 23, 2025Nucleus Network Ltd, Sionna Therapeutics Inc.
NCT05538585Phase 1Sep 27, 2022AbbVie
NCT05530278Phase 1Sep 20, 2022AbbVie
NCT04853368Phase 2Sep 13, 2021AbbVie
NCT03969888Phase 2Aug 27, 2019AbbVie
NCT03540524Phase 1May 31, 2018Galapagos NV
NCT03128606Phase 1Mar 28, 2017Galapagos NV
NCT03119649Phase 2Mar 18, 2017Galapagos NV
NCT03045523Phase 2Jan 1, 2017Galapagos NV
NCT03214614Phase 1Nov 14, 2016Galapagos NV
NCT02788721Phase 1May 1, 2016Galapagos NV, Pharmaceutical Research Associates, Inc. (PRA), SGS Life Sciences
NCT02662452Phase 1Jan 1, 2016Galapagos NV
Showing 12 of 12 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Galapagos NVFor profit7722016
AbbVieFor profit4422019
Nucleus Network LtdFor profit1012025
Pharmaceutical Research Associates, Inc. (PRA)For profit1012016
SGS Life SciencesFor profit1012016
Sionna Therapeutics Inc.For profit1112025
6 organizations
Page 1 / 1